Status | Study |
Recruiting |
Study Name: Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Condition: Primary Immune Deficiency Disorders Hemophagocytic Lymphohistiocytosis Date: 2014-08-28 Interventions: Biological: BPX-501 and AP1903 Single administration of BPX-501 T cells post partially-mismatched, relat |
Recruiting |
Study Name: Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies Condition: Sickle Cell Disease Transfusion Dependent Alpha- or Beta- Thalassemia Date: 2014-06-27 Interventions: Drug: Reduced Toxicity Ablative Regimen |
Recruiting |
Study Name: CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Condition: Chronic Myeloid Leukemia (CML) Acute Myelogenous Leukemia (AML); Date: 2014-02-11 Interventions: Device: CliniMACS CD34+ Reagent System |
Recruiting |
Study Name: CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease Condition: Bone Marrow Failure Syndrome Severe Aplastic Anemia Severe Date: 2013-10-17 Interventions: Biological: CD34 Stem Cell Selection Therapy The CliniMacs (PLUS) Reagent System (Miltenyi CliniMacs CD3 |
Recruiting |
Study Name: BMT Abatacept for Non-Malignant Diseases Condition: Hurler Syndrome Fanconi Anemia Glanzmann Thrombasthenia Date: 2013-07-24 Interventions: Drug: Abatacept All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis |
Active, not recruiting |
Study Name: Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Condition: Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remissi Date: 2012-02-06 Interventions: Drug: fludarabine phosphate Gi |
Suspended |
Study Name: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation Condition: Thalassemia Sickle Cell Disease Glanzmann Thrombasthenia Date: 2010-09-15 Interventions: Drug: Alefacept 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacep |
Recruiting |
Study Name: Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders Condition: Non-Malignant Date: 2009-06-11 Interventions: Procedure: Allogeneic Bone Marrow Transplantation |
Completed |
Study Name: Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment Condition: Dyskeratosis Congenita Fanconi Anemia Myelodysplastic Synd Date: 2007-07-10 Interventions: Genetic: polymerase chain reaction Other: |
Completed |
Study Name: Stem Cell Transplant for Bone Marrow Failure Syndromes Condition: Diamond-Blackfan Anemia Kostmann's Neutropenia Date: 2005-09-12 Interventions: Procedure: Stem cell transplant |